INT MEDICAL1501.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, INT MEDICAL (1501.HK) trades at a P/E of 24.60x, P/B of 2.04x, P/S of 4.73x, and a dividend yield of 0.84%.
Longitudinal percentile comparison: P/E sits at the 20th percentile over the trailing 10Y window (vs. 24th percentile over 3Y); P/B sits at the 8th percentile over the trailing 10Y window (vs. 2nd percentile over 3Y); P/S sits at the 7th percentile over the trailing 10Y window (vs. 5th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 66th percentile within its industry and the 79th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.84%, ranking at the 44th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 12.1 points, pointing to a consistent valuation read across both metrics. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. INT MEDICAL operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 1501 · SEHK: 1501 · 1501
Want the full picture on whether INT MEDICAL (1501.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 24.60 | ||||||
| P/B (MRQ) | 2.04 | ||||||
| P/S (TTM) | 4.73 | ||||||
| Dividend Yield | 0.84% | ||||||
| Buyback + Div Yield | 0.84% |